Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
OtherClinical Investigations (Human)
Open Access

Temporary reactive response of axillary lymph nodes to COVID-19 vaccination on 18F-rhPSMA-7.3 PET/CT in patients with prostate cancer

Susan Notohamiprodjo, Matthias Eiber, Christian Lohrmann and Wolfgang Andreas Weber
Journal of Nuclear Medicine March 2022, jnumed.121.263758; DOI: https://doi.org/10.2967/jnumed.121.263758
Susan Notohamiprodjo
Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Susan Notohamiprodjo
Matthias Eiber
Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Lohrmann
Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wolfgang Andreas Weber
Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Wolfgang Andreas Weber
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Vaccine-associated lymphadenopathy (VAL) is a common finding on 18F-FDG PET/CT examinations following Coronavirus disease 2019 (COVID-19) vaccination. However, data regarding VAL on 18F-rhPSMA-7.3-ligand PET are currently lacking. This study assesses its prevalence, temporal response to vaccination and characteristics of VAL. Methods: 233 consecutive vaccinated and 41 unvaccinated patients with confirmed prostate cancer who underwent 18F-rhPSMA-7.3 PET/CT were retrospectively analyzed. Size and uptake of the axillary lymph nodes were measured. Ratios of SUVmax of ipsilateral to contralateral axillary lymph node (SUVratio) were determined. The characteristics of SUVratio in respect to the duration of PSMA avidity in axillary lymph node after COVID-19 vaccination was analyzed. Results: The prevalence of VAL on 18F-rhPSMA-7.3 PET was 45%. Up to a period of 8 weeks following last COVID-19 vaccination SUVratio was positive (2.05 + 0.17). Thereafter, SUVratio dropped significantly (1.35 + 0.09) and approached the value of unvaccinated group (1.1 + 0.2). SUVratio of metastatic axillary lymph nodes was very high (>11) and can be easily detected visually or semi quantitatively. In 3 patients we observed suspected development and consecutively confirmed involving metastasis of axillary lymph node with SUVratio between 4.0 to 6.6. Correlation between SUVratio and lymph node size (r=0.93, p<0.0001) and lymph node size and duration following vaccine (r=-0.88, p<0.0008) was found. Conclusion: Increased uptake of the PSMA-ligand 18F-rhPSMA-7.3 by axillary lymph nodes is common after COVID-19 vaccination and can persist for 8 weeks. This finding should be considered in the interpretation of 18F-rhPSMA-7.3 PET/CT examinations.

  • Oncology: GU
  • PET
  • PET/CT
  • Other
  • COVID-19 vaccine
  • PSMA-ligand PET/CT
  • axillary lymphadenopathy
  • rhPSMA

Footnotes

  • Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: https://jnm.snmjournals.org/page/permissions.

  • Copyright © 2022 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 63, Issue 5
May 1, 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Temporary reactive response of axillary lymph nodes to COVID-19 vaccination on 18F-rhPSMA-7.3 PET/CT in patients with prostate cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Temporary reactive response of axillary lymph nodes to COVID-19 vaccination on 18F-rhPSMA-7.3 PET/CT in patients with prostate cancer
Susan Notohamiprodjo, Matthias Eiber, Christian Lohrmann, Wolfgang Andreas Weber
Journal of Nuclear Medicine Mar 2022, jnumed.121.263758; DOI: 10.2967/jnumed.121.263758

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Temporary reactive response of axillary lymph nodes to COVID-19 vaccination on 18F-rhPSMA-7.3 PET/CT in patients with prostate cancer
Susan Notohamiprodjo, Matthias Eiber, Christian Lohrmann, Wolfgang Andreas Weber
Journal of Nuclear Medicine Mar 2022, jnumed.121.263758; DOI: 10.2967/jnumed.121.263758
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Clinical Investigations (Human)

  • Using, 68Ga-PSMA-11 PET/CT for therapy response assessment in patients with metastatic castration-resistant prostate cancer: an application of EAU/EANM recommendations in clinical practice.
  • Correlation of 68Ga-RM2 PET with Post-Surgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer
  • 68Ga-PSMA-11 PET/MRI in patients with newly diagnosed intermediate or high-risk prostate adenocarcinoma: PET findings correlate with outcomes after definitive treatment
Show more Clinical Investigations (Human)

Clinical (Oncology: Other)

  • CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody
  • Dual-tracer PET/CT protocol with [18F]-FDG and [68Ga]Ga-FAPI-46 for cancer imaging - a proof of concept.
  • The Importance of Training, Accreditation and Guidelines for The Practice of Theranostics: The Australian Perspective
Show more Clinical (Oncology: Other)

Similar Articles

Keywords

  • Oncology: GU
  • PET
  • PET/CT
  • Other
  • COVID-19 vaccine
  • PSMA-ligand PET/CT
  • axillary lymphadenopathy
  • rhPSMA
SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire